盐酸羟甲唑啉(Oxymetazoline Hydrochloride) - 药物靶点：α1A-AR_在研适应症：眼睑下垂，红斑，玫瑰痤疮_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol

+ [39]

靶点

α1A-AR

作用机制

α1A-AR激动剂(肾上腺素能受体α-1a激动剂)

治疗领域

心血管疾病眼部疾病耳鼻咽喉疾病+ [4]

在研适应症

眼睑下垂红斑玫瑰痤疮+ [4]

非在研适应症

老花眼脊髓损伤尿失禁

原研机构

Schering-Plough Canada, Inc.

在研机构

Schering-Plough Canada, Inc.

Mayne Pharma Ltd.

Santen Pharmaceutical Co., Ltd.

+ [6]

非在研机构

Allergan Ltd. (Ireland)Bayer Healthcare LLCAllergan Plc /Icahn/

最高研发阶段批准上市

首次获批日期

加拿大 (1964-12-31)

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构

分子式C16H25ClN2O

InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N

CAS号2315-02-8

关联

79

项与盐酸羟甲唑啉相关的临床试验

NCT06514612 / Not yet recruiting临床3期

A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) Used Twice Daily (BID) in the Treatment of Acquired Blepharoptosis

A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis

开始日期2025-03-01

申办/合作机构

Santen SAS

NCT06683651 / Recruiting临床3期

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis

This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
At present, there are no medicines for the treatment of acquired blepharoptosis in China.
Therefore, to evaluate the efficacy and safety of 0.1% STN1013800 ophthalmic solution, Vehicle (Placebo) are designed.
For the screening period, 3-7 days were set to confirm the subjects and judge their qualification. Dosage and administration were based on prior clinical trial results approved at 0.1% once daily for 42 days treatment.

开始日期2024-10-22

申办/合作机构

Santen Pharmaceutical Co., Ltd.

CTR20242719 / Recruiting临床3期

盐酸羟甲唑啉滴眼液治疗中国成人获得性上睑下垂患者有效性、安全性和药代动力学特征的多中心、随机、双盲、安慰剂平行对照Ⅲ期临床试验

评价盐酸羟甲唑啉滴眼液在中国成人获得性上睑下垂患者中的有效性、安全性和药代动力学（PK）特征。

开始日期2024-10-10

申办/合作机构

南京恒道医药科技股份有限公司

[+1]

100 项与盐酸羟甲唑啉相关的临床结果

登录后查看更多信息

100 项与盐酸羟甲唑啉相关的转化医学

登录后查看更多信息

100 项与盐酸羟甲唑啉相关的专利（医药）

登录后查看更多信息

1,118

项与盐酸羟甲唑啉相关的文献（医药）

2025-01-01·CLINICAL OTOLARYNGOLOGY

The Anaesthetic Efficacy of Tetracaine and Oxymetazoline Compared With Co‐Phenylcaine in Healthy Individuals

Article

作者: Douglas, Richard G. ; Lengyel, Olivia ; Louis, Deanna ; Hale, Samuel J. M. ; Kim, Raymond

ABSTRACT:

Objectives:

Nasal anaesthetic‐decongestant sprays are commonly used prior to nasal instrumentation, such as flexible and rigid nasal endoscopy. Co‐phenylcaine (lignocaine 5%, phenylephrine 0.5%, ENT Technologies Pty Ltd., Melbourne, VIC, Australia) is a combination spray commonly used for this purpose. However, lignocaine is less potent than other local anaesthetics, and both active constituents of Co‐phenylcaine have a bitter taste. It was hypothesised that a combination spray containing tetracaine and oxymetazoline would both offer more potent topical anaesthesia and have a better taste.

Methods:

Four anaesthetic‐decongestant nasal sprays were tested in 10 healthy participants (Co‐phenylcaine, and tetracaine 0.5%, 1% and 2% with oxymetazoline 0.05%). Sensory thresholds were sequentially measured at the head of the inferior turbinate using Semmes‐Weinstein monofilaments over the following hour. Participants also rated taste on a Likert‐style scale, and reported whether they experienced subjective numbness of the maxillary teeth.

Results:

A median peak sensory threshold of 60 g (the maximum tested) was observed with Co‐phenylcaine, but this threshold was exceeded by all the tetracaine‐based sprays. Tetracaine 2% with oxymetazoline 0.05% had a significantly more rapid onset than Co‐phenylcaine (4 min vs. 6 min, p < 0.05) and a longer duration of action. Eight participants reported dental numbness after administration of tetracaine 2% with oxymetazoline 0.05%, but only one participant after Co‐phenylcaine. Tetracaine‐based sprays were generally perceived to taste less unpleasant than Co‐phenylcaine.

Conclusion:

Tetracaine 2% with oxymetazoline 0.05% is a more potent and rapidly acting anaesthetic‐decongestant spray than Co‐phenylcaine, with a longer duration of action.

2024-12-01·International Forum of Allergy & Rhinology

Oxymetazoline as a predictor of turbinate reduction surgery outcomes: Objective support from a prospective, single‐blinded, computational fluid dynamics study

Article

作者: Formanek, Veronica L. ; Otto, Bradley A. ; Schneller, Aspen R. ; Root, Zachary T. ; Kelly, Kathleen M. ; Zhao, Kai ; Chapman, Robbie J. ; Wu, Zhenxing ; Lepley, Thomas J.

Abstract:

Background:

A patient's subjective response to topical nasal decongestant is often used to screen for turbinate reduction surgery suitability. However, this anecdotal strategy has not been objectively and quantitatively evaluated.

Methods:

Prospective, longitudinal, and single‐blinded cohort study employing computational fluid dynamic modeling based on computed tomography scans at baseline, 30 min postoxymetazoline, and 2 months postsurgery on 11 patients with chronic turbinate hypertrophy.

Results:

Nasal obstruction symptom evaluation (NOSE) and visual analogue scale (VAS) obstruction scores significantly improved from baseline to postoxymetazoline and again to postsurgery (NOSE: 71.82 ± 14.19 to 42.27 ± 25.26 to 22.27 ± 21.04; VAS: 6.09 ± 2.41 to 4.14 ± 2.20 to 2.08 ± 1.56; each interaction p < 0.05), with significant correlation between the latter two states (r∼0.37–0.69, p < 0.05). Oxymetazoline had a broader anatomical impact throughout inferior and middle turbinates than surgery (many p < 0.05); however, the improvement in regional airflow is similar (most p > 0.05) and predominantly surrounding the inferior turbinate. Strong postoxymetazoline to postsurgery correlations were observed in decreased nasal resistance (r = 0.79, p < 0.05), increased regional airflow rates (r = ‐0.47 to −0.55, p < 0.05) and regional air/mucosa shear force and heat flux (r = 0.43 to 0.58, p < 0.05); however, only increasing peak heat flux significantly correlated to symptom score improvement (NOSE: r = 0.48, p < 0.05).

Conclusion:

We present the first objective evidence that the “topical decongestant test” can help predict turbinate reduction surgery outcomes. The predictive effect is driven by similar improvementin regional airflow that leading to improved air/mucosa stimulations (peak heat flux) rather than through reduced nasal resistance.

2024-11-01·OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Even Patients Who Respond Poorly to the Phenylephrine Test Can Benefit From Topical Oxymetazoline for Temporary Eyelid Ptosis Management

Article

作者: Ohkawara, Lilian E. ; Gameiro, Gustavo R. ; Iwakura, Julia H. ; Osaki, Tammy H. ; Osaki, Midori H.

65

项与盐酸羟甲唑啉相关的新闻（医药）

2024-11-21

·Business Wire

Nasal Sprays Help Alleviate Nasal Congestion

AMERICAN FORK, Utah--( BUSINESS WIRE )--Today, Nathan Jones, CEO of Xlear Inc., a consumer hygiene products company, released this statement regarding the FDA’s proposal to remove popular over-the-counter decongestants, which contain the drug phenylephrine, from the market: “With the FDA concluding that this common decongestant isn’t effective, as we enter cold and flu season, and as families prepare to celebrate the holidays, many Americans need a new answer for the discomfort of sinus congestion,” Jones noted. “For people looking for help, the U.S. Centers for Disease Control (CDC) Guidance, ‘Relief for Symptoms of Colds and Coughs’, ‘instructions’ say to ‘use saline nasal spray to relieve congestion.’ i Similarly, CDC’s ‘Sinus Infection Basics’ say ‘How to Feel Better’ ‘use a . . . saline nasal spray,’” ii he pointed out. “You experience congestion because there is an irritant or pathogen in your upper airway that your body is trying to trap and wash away—your runny nose is your body flushing it out. Saline-based nasal sprays can help speed up that flushing, reduce pathogen load, and make it more effective. It’s commonsense: The faster the bad stuff is gone, the faster you feel better,” Jones added. “For congestion caused by pathogens—like colds and flus—people can enhance that effect by using a nasal spray that contains xylitol. A series of studies show xylitol (a natural sugar) deactivates and/or blocks the adhesion of many types of viruses and bacteria, to your airway cells,” iii Jones continued. Adhesion is the process by which a pathogen attaches to your tissue to initiate infection. Using a nasal spray with xylitol helps block adhesion of these pathogens. For example, a Randomized Controlled (clinical) Trial published in 2022, determined that a saline-nasal spray containing xylitol and other ingredients reduced the rate of COVID-19 infections by 62 percent above placebo. iv “Using a basic saline would be comparable to rinsing your hands with water; using a nasal spray with xylitol, like Xlear , would be comparable to washing your hands with soap. Expect more from your nasal hygiene products. Make sure they have xylitol so you can better and faster clean out the bad stuff while alleviating the congestion,” Jones added. Xlear nasal spray is a saline-based nasal spray containing xylitol. Xlear 12 Hour Nasal Decongestant is a saline-based nasal spray containing xylitol and the decongestant Oxymetazoline HCL. For more information on Xlear please visit www.xlear.com . ____________________________ i https://www-cdc-gov.libproxy1.nus.edu.sg/antibiotic-use/media/pdfs/HCP-Relief-Colds-Cough-85by11-P.pdf ii https://www-cdc-gov.libproxy1.nus.edu.sg/sinus-infection/about/index.html iii For example: T Kontiokari, M Uhari, M Koskela, Antiadhesive effects of xylitol on otopathogenic bacteria., Journal of Antimicrobial Chemotherapy , Volume 41, Issue 5, May 1998, Pages 563–565, https://academic-oup-com.libproxy1.nus.edu.sg/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext - google_vignette ; Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy , 41 (5), 563–565, https://academic-oup-com.libproxy1.nus.edu.sg/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext&login=false ; Jung, Kie Hoon. (2021). Antiviral Efficacy Against Virus Infections in Human-Derived Tracheal/Bronchial Epithelial Cells. Utah State University, https://xlrtmp.com/wp-content/uploads/2023/05/Antiviral-efficacy_USU2021.pdf ; Vega, J. C., et al., (2020). Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. BioRxiv , https://professionals.xlear.com/portfolio/anti-adherence-of-viruses/ ; Ruiz, V., Rodríguez-Cerrato, V., Huelves, L. et al. Adherence of Streptococcus pneumoniae to Polystyrene Plates and Epithelial Cells and the Antiadhesive Potential of Albumin and Xylitol. Pediatr Res 69, 23–27, https://www-nature-com.libproxy1.nus.edu.sg/articles/pr920116 - citeas . iv Damian Balmforth, et al., Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial., Journal of Clinical Virology, 155; 2022, https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/pii/S1386653222001809 .

2024-11-21

·蒲公英Ouryao

上海：2024年第3期药品质量抽检通告发布

转自：上海市药监局编辑：水晶 11月21日，上海市药监局发布了2024年第3期药品质量抽检通告，9批次药品不合格。不合格药品（检测项目）：中药饮片7批次：玄参（含量测定）、薤白（水分）、天麻（水分）、蜂房（黄曲霉毒素）、白芍（二氧化硫残留量）、知母（含量测定）、浮萍（水分）。药包材1批次：药用铝箔（易氧化物）。非无菌制剂1批次：盐酸羟甲唑啉喷雾剂（每瓶总喷数）。对抽检不符合规定批次产品，各级药品监管部门已要求相关企业采取停售、停用、召回等风险控制措施，并对相关企业依法查处。

上市批准

2024-10-29

·Business Wire

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

EMERYVILLE, Calif.--( BUSINESS WIRE )-- NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC (“Refresh”) for an affiliate of Refresh to acquire the Company’s Avenova ® brand and related assets is a “Superior Proposal” to the Company’s asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC (“PRN”). Refresh’s unsolicited offer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicited offer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price. The Company has notified PRN of the board of directors’ determination and that the Company intends to terminate its asset purchase agreement with PRN unless the Company receives a revised proposal from PRN by 11:59 p.m. Pacific time on November 4, 2024, such that the Company’s board of directors determines that Refresh’s unsolicited offer is no longer a Superior Proposal, in accordance with the process provided in the asset purchase agreement with PRN. “After careful consideration, our board of directors determined that the unsolicited offer by Refresh represents greater value for our stockholders while also placing Avenova in highly capable commercial hands,” said Justin Hall, NovaBay CEO. “Refresh is an affiliate company of RVL Pharmaceuticals, which is commercializing Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved prescription eye drops for adults with low-lying eyelids, also known as acquired blepharoptosis or ptosis. Our Avenova products are highly complementary to this non-surgical solution that quickly lifts eyelids for more awake-looking eyes. Further, RVL Pharmaceuticals and NovaBay are aligned in our shared passion for commercializing products that improve patients’ lives.” The Company’s asset purchase agreement with PRN, in accordance with such agreement, remains in full force and effect, and the Company’s board of directors has not withdrawn or modified its recommendation regarding stockholders approving the pending transaction with PRN. The Company’s transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval. Consistent with its fiduciary duties, the Company’s board of directors conducted a comprehensive evaluation of the Refresh unsolicited offer with assistance from independent financial and legal advisors, before making its determination. About NovaBay Pharmaceuticals, Inc. NovaBay's leading product Avenova ® Lid & Lash Cleansing Spray is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. All Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com . Forward-Looking Statements This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management’s current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the contemplated transaction with PRN, the unsolicited offer by Refresh and related matters. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the Securities and Exchange Commission (the “SEC”) and the Special Meeting Proxy Statement (as defined below), especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law. Additional Information and Where to Find It In connection with the solicitation of proxies, on October 16, 2024, NovaBay filed a definitive proxy statement with the SEC with respect to the special meeting to be held in connection with the proposed asset sale to PRN and a potential voluntary liquidation and dissolution of the Company (the “Special Meeting Proxy Statement”). Promptly after filing the Special Meeting Proxy Statement with the SEC, NovaBay mailed the Special Meeting Proxy Statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the contemplated asset sale to PRN and potential dissolution. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT NOVABAY HAS FILED OR WILL FILE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by NovaBay with the SEC in connection with the contemplated asset sale to PRN and potential dissolution at the SEC's website ( http://www.sec.gov ) or at the Company’s investor relations website https://novabay.com/investors/ ) or by writing to NovaBay Pharmaceuticals, Inc., Investor Relations, 2000 Powell Street, Suite 1150, Emeryville, CA 94608. The information provided on, or accessible through, our website is not part of this communication, and therefore is not incorporated herein by reference. Participants in the Solicitation NovaBay and its directors and executive officers may be deemed to be participants in the solicitation of proxies from NovaBay's stockholders in connection with the contemplated asset sale to PRN and the potential dissolution. A list of the names of the directors and executive officers of the Company and information regarding their interests in the contemplated asset sale to PRN and the potential dissolution, including their respective ownership of the Company’s common stock and other securities is contained in the Special Meeting Proxy Statement. In addition, information about the Company’s directors and executive officers and their ownership in the Company is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and filed with the SEC on March 26, 2024, as amended on March 29, 2024 and as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Socialize and Stay Informed on NovaBay ’ s Progress Like us on Facebook Follow us on X Connect with NovaBay on LinkedIn Visit NovaBay’s Website Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email sales@avenova.com Avenova.com

并购

100 项与盐酸羟甲唑啉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01022	盐酸羟甲唑啉	R01AA05 S01GA04 R01AB07	DB00935

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
眼睑下垂	美国	RVL Pharmaceuticals, Inc.	2020-07-08
红斑	美国	Mayne Pharma Ltd.	2017-01-18
充血	日本	Sato Pharmaceutical Co., Ltd.	2007-08-01
鼻塞	中国	常州亚邦制药有限公司	1992-01-01
玫瑰痤疮	美国	Bayer Healthcare LLC	1986-05-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
睑裂狭小	临床3期	-	Santen SAS	2025-03-01
大便失禁	临床2期	匈牙利	RDD Pharma Ltd.	2014-11-01
脊髓损伤	临床2期	匈牙利	RDD Pharma Ltd.	2014-11-01
尿失禁	临床2期	匈牙利	RDD Pharma Ltd.	2014-11-01
老花眼	临床2期	美国	Allergan Ltd. (Ireland)	2014-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05715346 (CTgov)	临床1/2期	眼睑下垂	33	LEV102 2.0% (LEV102 Topical Gel, 2.0%)	繭範窪襯鑰鑰鹹夢鬱鹽(觸艱觸鏇範鹽憲齋顧淵) = 衊窪簾壓齋醖鏇鹹餘醖願鏇鬱選糧襯蓋獵鬱積 (壓憲糧膚構鬱糧餘淵構, 願築鹽鹹鑰艱艱觸選遞 ~ 鹹鏇壓範衊醖獵膚艱夢) 更多	-	2024-11-13
				LEV102 1.0% (LEV102 Topical Gel, 1.0%)	繭範窪襯鑰鑰鹹夢鬱鹽(觸艱觸鏇範鹽憲齋顧淵) = 鬱願願簾鬱壓願顧壓製願鏇鬱選糧襯蓋獵鬱積 (壓憲糧膚構鬱糧餘淵構, 齋觸夢憲觸鑰壓選構艱 ~ 鬱範壓廠鑰壓憲齋構獵) 更多
AAD2023	N/A	痤疮瘢痕	30	OxH 0.05% solution	衊夢淵鬱糧範觸鏇壓鏇(網齋遞壓遞齋憲鑰醖齋) = 鬱醖築壓繭製窪齋窪鹹鹹膚繭製顧壓醖觸窪鑰 (觸獵鬱願糧衊鹽鹹衊鑰 )	积极	2023-03-17
				Placebo	衊夢淵鬱糧範觸鏇壓鏇(網齋遞壓遞齋憲鑰醖齋) = 鏇襯夢蓋蓋蓋觸顧繭淵鹹膚繭製顧壓醖觸窪鑰 (觸獵鬱願糧衊鹽鹹衊鑰 )
Pubmed \| J Plast Reconstr Aesthet Surg	N/A	-	114	Topical oxymetazoline 0.1%	夢衊蓋網觸襯艱糧壓鏇(鹽窪網醖憲築淵窪選遞) = 襯糧齋艱築觸獵醖壓糧艱蓋製網膚醖遞齋願獵 (襯齋範齋醖糧鹹鬱糧範 )	积极	2023-02-09
NCT04153188 (CTgov)	临床4期	-	34	The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream)	簾糧憲襯齋憲獵積顧鹽(壓糧鏇蓋鑰繭艱範醖鹹) = 築選積範糧膚窪願糧積簾憲獵鹹積壓艱選鹹範 (築鏇淵糧獵積鬱鑰鬱糧, 構鏇鬱製淵鹹製鑰鑰壓 ~ 鬱範鹽艱顧遞齋鬱網廠) 更多	-	2022-03-18
				Oxymetazoline HCL 1% Cream (Oxymetazoline HCL 1% Cream)	簾糧憲襯齋憲獵積顧鹽(壓糧鏇蓋鑰繭艱範醖鹹) = 顧廠觸顧窪選遞範齋鹹簾憲獵鹹積壓艱選鹹範 (築鏇淵糧獵積鬱鑰鬱糧, 構齋鏇淵鑰獵鬱顧鬱繭 ~ 糧鏇窪選獵範簾糧衊襯) 更多
NCT01848041 (CTgov)	临床1/2期	眼睑下垂	46	RVL-1201 (RVL-1201 Once Daily)	壓廠製簾鑰獵膚網遞餘(繭鏇窪鏇廠鬱壓遞鏇淵) = 鏇鹽製糧構鑰壓簾壓繭艱鬱積觸淵構獵鹹壓簾 (餘憲夢顧淵繭夢範繭淵, 鹹衊蓋顧夢簾選餘糧範 ~ 鑰蓋糧獵鬱醖願繭衊廠) 更多	-	2021-07-22
				RVL-1201 (RVL-1201 Twice Daily)	壓廠製簾鑰獵膚網遞餘(繭鏇窪鏇廠鬱壓遞鏇淵) = 範夢膚顧範夢積願鬱範艱鬱積觸淵構獵鹹壓簾 (餘憲夢顧淵繭夢範繭淵, 廠夢選鏇構糧築構遞鑰 ~ 積築廠鏇鬱鏇鬱艱壓壓) 更多
NCT03954444 (CTgov)	临床3期	玫瑰痤疮	1,105	Oxymetazoline Hydrochloride (Oxymetazoline Hydrochloride Cream, 1%)	鹽鬱淵糧糧願願齋鬱構(壓艱獵膚廠廠願憲繭壓): Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0)	-	2021-06-23
				Rhofade Cream, 1% (RHOFADE Cream, 1%)
NCT03228914 (CTgov)	临床4期	出血 \| 鼻息肉	20	Oxymetazoline (Oxymetazoline)	蓋積鑰襯壓鬱鹹簾壓顧(範膚淵築繭齋醖構蓋餘) = 獵膚構淵壓繭鬱鏇餘淵醖觸顧築簾範鑰選鹽繭 (構鹹齋願醖鬱製範範製, 鹹願鏇簾選糧選鹽壓簾 ~ 衊鏇窪淵遞膚糧鹹鏇鹽) 更多	-	2021-01-13
				Epinephrine (Epinephrine)	蓋積鑰襯壓鬱鹹簾壓顧(範膚淵築繭齋醖構蓋餘) = 簾糧廠選選網選醖顧鹽醖觸顧築簾範鑰選鹽繭 (構鹹齋願醖鬱製範範製, 蓋膚醖夢膚網鏇選網醖 ~ 選繭簾鏇鏇鹹餘壓鹽夢) 更多
NCT03352323 (CTgov)	临床3期	玫瑰痤疮 \| 红斑	50	Oxymetazoline	膚選壓鬱網衊築餘積衊(齋繭網襯醖製窪鏇憲範) = 醖製顧餘鬱網選範餘鏇顧積簾壓構膚窪鹽構簾 (襯積壓夢壓襯齋遞鏇醖, 醖餘範繭築積獵築醖廠 ~ 獵壓襯繭壓餘選簾艱壓) 更多	-	2021-01-05
NCT02595528 (CTgov)	临床2期	老花眼	163	AGN-190584 (AGN-190584 Vehicle)	鏇壓艱淵糧憲鹽觸窪蓋(襯夢廠積齋鹹顧遞餘鏇) = 餘鬱膚顧夢遞遞窪製鏇襯憲衊鹹製蓋觸蓋遞壓 (遞膚構製糧襯築鑰獵獵, 窪遞願製繭鬱築鏇膚鹽 ~ 構襯獵廠壓壓繭願鹹廠) 更多	-	2020-12-22
				AGN-190584 (AGN-190584 Lower Dose)	鏇壓艱淵糧憲鹽觸窪蓋(襯夢廠積齋鹹顧遞餘鏇) = 壓積蓋艱壓齋衊願鬱鏇襯憲衊鹹製蓋觸蓋遞壓 (遞膚構製糧襯築鑰獵獵, 觸憲齋艱顧齋壓選壓鹹 ~ 鑰憲構蓋蓋醖選範願鏇) 更多
NCT02780115 (CTgov)	临床2期	老花眼	151	AGN-190584 Vehicle	壓製淵鹽蓋廠鏇膚獵鹽(襯簾選衊廠艱遞簾鏇鑰) = 鑰鹹廠鹹製積衊顧範衊繭願醖鹽製壓鏇積顧壓 (壓繭淵窪壓鏇衊淵築醖, 壓遞襯選膚顧製齋廠鹽 ~ 衊鬱築鏇壓築膚蓋遞廠) 更多	-	2020-12-22